This was an independent session organised by MGP without financial support or involvement from the pharmaceutical industry.
This site is intended for UK healthcare professionals
Dr Kevin Fernando Q&A on type 2 diabetes
Dr Kevin Fernando answers questions on the impact of type 2 diabetes on patients’ daily lives, differences between NICE and SIGN guidance, and key take-home messages for primary care
Latest video
Related articles
On demand webinarsReal-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer. View prescribing information Video: DPP-4 inhibitors webinar Click here to complete the feedback and receive your CPD certificate ...
- Independent professional body guideline
Type 2 diabetes pharmacological management pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
- Working party guideline/algorithm
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
![20200212 Guidelines comparison tablev10 [online] UPDATED 2020 v4](https://d3j7puhwqgd8ts.cloudfront.net/Pictures/100x67//9/3/4/6934_20200212guidelinescomparisontablev10onlineupdated2020v4_419801.png)
More Videos
- Video
Dr Glenis Scadding Q&A on rhinitis
This session was supported by an educational grant from Mylan Ltd. Dr Glenis Scadding comments on the main presentations of rhinitis, its impact on patients’ daily lives, red flags for referral, and the main recommendations of the 2017 BSACI guideline
- Video
Guidelines Live 2018 overview with Dr Matthew Fay
Dr Matt Fay, Chair of Guidelines Live 2018, provides his thoughts on the programme from a primary care perspective, and summarises the meetings.
No comments yet